Download PDF

1. Company Snapshot

1.a. Company Description

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.


In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools.The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations.It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries.


The company was formerly known as Cytoville, Inc.and changed its name to Cytek Biosciences, Inc.in August 2015.


Cytek Biosciences, Inc.was founded in 1992 and is headquartered in Fremont, California.

Show Full description

1.b. Last Insights on CTKB

Cytek Biosciences' recent performance was negatively impacted by a wider-than-expected loss of $0.09 per share in Q1 2025, surpassing the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.05 per share in the same period last year. The company's operating expenses represented 65.67% of its sales in 2024, indicating a high burn rate. Additionally, Cytek's Q1 2025 earnings release highlighted a decline in revenue, which fell short of analyst estimates.

1.c. Company Highlights

2. Cytek Biosciences' Q4 2025 Earnings: A Mixed Bag

Cytek Biosciences reported a revenue of $62.1 million for Q4 2025, an 8% year-over-year increase, with GAAP gross profit at $32.9 million, a 2% decline versus the prior year quarter. The adjusted gross profit margin was 55%, down from 61% in the prior year quarter. The company's EPS came out at -$0.3439, missing estimates of $0.02. For the full year 2025, total revenue was $201.5 million, a 1% increase over the prior year, while GAAP gross profit was $104.5 million, a decrease of 6% compared to the prior year.

Publication Date: Mar -02

📋 Highlights
  • Record Q4 Revenue:: Achieved $62.1 million, an 8% YoY increase and the highest quarterly revenue in company history.
  • Recurring Revenue Growth:: Represented 34% of total revenue in 2025, growing 21% YoY.
  • Regional Performance:: APAC revenue rose 15% YoY, driven by instrument, service, and reagent growth; EMEA and U.S. saw stabilization and double-digit service revenue growth.
  • Margin Pressure:: Adjusted gross margin fell to 55% in Q4 2025 from 61% in Q4 2024, with operating expenses up 25% YoY to $38.5 million.
  • 2026 Outlook:: Revenue guidance set at $205–212 million, reflecting improved U.S./EMEA markets and sustained APAC growth.

Geographic Performance

The company's geographic performance was mixed, with EMEA and APAC posting double-digit year-over-year revenue increases in Q4, while the U.S. grew 5%. APAC revenue grew 15% in Q4, driven by growth in instrument, service, and reagent revenue. According to Wenbin Jiang, "revenue growth was driven by stabilization and growth in the U.S., a turnaround in the EU, continued strength in APAC, and solid expansion of recurring revenue businesses worldwide."

Recurring Revenue and Software Ecosystem

Cytek's recurring revenue continued to strengthen, representing 34% of total revenue in 2025 and growing 21% year-over-year. The company's software ecosystem, including the Cytek Cloud, is a powerful growth driver, with over 24,000 users by year-end 2025. This is a significant development, as it indicates a growing and loyal customer base.

Operating Expenses and Cash Position

Total operating expenses were $38.5 million, up $7.8 million or 25% versus Q4 2024. Loss from operations was $5.6 million for Q4. The company's cash and marketable securities decreased to $261.5 million at December 31, 2025, from $261.7 million at the end of the third quarter.

Outlook and Valuation

For 2026, the company initiated a revenue outlook of $205 million to $212 million, assuming constant currency exchange rates. Analysts estimate next year's revenue growth at 8.3%. With a P/S Ratio of 2.84 and an EV/EBITDA of -31.11, the market is pricing in significant growth expectations. The current valuation metrics indicate that the market has high expectations for the company's future performance.

Conclusion on Financial Health

The company's financial health is a concern, with a Net Debt / EBITDA of 4.82 and a ROE of -18.01%. The adjusted EBITDA was $5 million in 2025, a decline of $17.4 million from $22.4 million in 2024. The company's commitment to improving these metrics going forward will be crucial in restoring investor confidence.

3. NewsRoom

Card image cap

Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

Mar -09

Source: globenewswire.com

Card image cap

Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference

Mar -09

Source: defenseworld.net

Card image cap

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Feb -27

Source: zacks.com

Card image cap

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Feb -27

Source: seekingalpha.com

Card image cap

Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results  and Provides 2026 Outlook

Feb -26

Source: globenewswire.com

Card image cap

Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference

Feb -18

Source: globenewswire.com

Card image cap

Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb -12

Source: globenewswire.com

Card image cap

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan -15

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.75%)

6. Segments

Full Spectrum Flow Cytometry Platform

Expected Growth: 10%

Cytek Biosciences' Full Spectrum Flow Cytometry Platform growth is driven by increasing adoption in research and clinical applications, advancements in AI-powered data analysis, expanding use in immunology and oncology, growing demand for high-parameter analysis, and increasing investments in life sciences research and development.

Service

Expected Growth: 14%

Cytek Biosciences' 14% growth is driven by increasing adoption of its innovative flow cytometry solutions, expanding customer base in biotech and pharma, and growing demand for high-parameter analysis in immunology and oncology research. Additionally, strategic partnerships and investments in R&D are fueling product development and commercialization, further propelling growth.

7. Detailed Products

Aurora

A high-parameter flow cytometer that enables simultaneous detection of up to 50 colors, allowing for in-depth analysis of complex biological systems

Northern Lights

A fully integrated, high-performance flow cytometer that enables high-dimensional analysis of cells and particles

Aurora CS

A high-parameter flow cytometer designed for core facilities and high-throughput laboratories

Full Spectrum Profiling (FSP) reagents

A comprehensive portfolio of flow cytometry reagents designed to work seamlessly with Cytek's instruments

Cytek Analytics Software

A comprehensive software platform for data analysis and visualization of high-dimensional flow cytometry data

8. Cytek Biosciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Cytek Biosciences, Inc. is medium due to the presence of alternative technologies and products in the market, but the company's unique offerings and strong brand reputation mitigate this threat.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Cytek Biosciences, Inc.'s products and services, which limits customers' ability to negotiate prices or switch to alternative suppliers.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the presence of multiple suppliers in the market, but Cytek Biosciences, Inc.'s strong relationships with its suppliers and its ability to negotiate prices mitigate this threat.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for life sciences and diagnostics products, which attracts new companies to enter the market, increasing competition for Cytek Biosciences, Inc.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established competitors in the market, which leads to aggressive marketing and pricing strategies, increasing competition for Cytek Biosciences, Inc.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 5.69%
Debt Cost 8.07%
Equity Weight 94.31%
Equity Cost 10.85%
WACC 10.69%
Leverage 6.03%

11. Quality Control: Cytek Biosciences, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rapid Micro Biosystems

A-Score: 4.2/10

Value: 7.1

Growth: 3.6

Quality: 3.4

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NeuroOne Medical Technologies

A-Score: 4.0/10

Value: 6.8

Growth: 5.7

Quality: 4.2

Yield: 0.0

Momentum: 6.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
ClearPoint Neuro

A-Score: 3.9/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 8.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cytek Biosciences

A-Score: 3.7/10

Value: 5.7

Growth: 7.0

Quality: 4.0

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Accelerate Diagnostics

A-Score: 3.4/10

Value: 10.0

Growth: 5.4

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Pulmonx

A-Score: 3.1/10

Value: 8.5

Growth: 4.7

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.99$

Current Price

3.99$

Potential

-0.00%

Expected Cash-Flows